Biohaven (BHVN) shares were lower premarket Monday after the biopharmaceutical company said a study of its experimental drug for spinal muscular atrophy did not achieve a "statistically significant difference" compared with placebo and standard of care at 48 weeks.
The company said the experimental treatment "showed clinically meaningful improvements" in motor function for patients in the study.
Biohaven said it intends to accelerate taldefgrobep alpha clinical plans in Q4 and engage with the US Food and Drug Administration on a path forward for the treatment.
Spinal muscular atrophy is a disorder characterized by the loss of motor neurons, atrophy of limb muscles, and muscle weakness that is often fatal.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。